Full Press Release Details
TDR August 2006 internal report; 2. 2012 Eisai Annual Report; 3. Wolters Kluwer 1 2 3 A.P. Pharma Product Lifecycle Considerations 33 APF530 covered by multiple patents 2 patents covering combination of polymer, excipients and drug expire in 2021 3 patents covering APF530 expire in 2024 Polymer based injectable products are difficult to copy independent of IP ANDA FDA requirements for injectable products Must have same inactive ingredients in the same concentration as the reference listed drug Polymers are complex mixtures of varying length molecules, making characterization for sameness very challenging July 2013 2013.
Does not include outstanding warrants for 81.1 million shares with weighted average exercise price of $0.22/share, nor shares issuable upon conversion of notes convertible for up to 120.3 million shares based on a rate of 25,000 shares for every $1,000 of principal, nor currently exercisable employee stock options for up to 27.1 million shares with weighted average exercise price of $0.38/share. 2 As of March 31, 2013 3 July 2013 2013.
Company Overview OTCBB: APPA July 2013 Exhibit 99.1 Legal Disclaimer This presentation contains forward looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward looking statements involve risks and uncertainties, including uncertainties associated with timely development, approval, launch and acceptance of new products, satisfactory completion of clinical studies, establishment of new corporate alliances, progress in research and development programs and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission.